{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=radiation&page=2", "query": { "intervention": "radiation", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=radiation&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-16T20:34:55.421Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05255107", "title": "Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Previously Untreated Corneal Ulcers", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Keratitis", "Corneal Ulcer" ], "interventions": [ { "name": "Standard of Care Therapy + CXL + Riboflavin 0.23% L Solution", "type": "COMBINATION_PRODUCT" }, { "name": "Standard of Care Therapy + Sham CXL + Artificial Tears", "type": "OTHER" } ], "intervention_types": [ "COMBINATION_PRODUCT", "OTHER" ], "sponsor": "Peschke GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 468, "start_date": "2022-03-14", "completion_date": "2024-02-24", "has_results": false, "last_update_posted_date": "2022-10-28", "last_synced_at": "2026-09-16T20:34:55.421Z", "location_count": 12, "location_summary": "Littleton, Colorado • Fort Myers, Florida • Tampa, Florida + 9 more", "locations": [ { "city": "Littleton", "state": "Colorado" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Teaneck", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05255107" }, { "nct_id": "NCT00119392", "title": "Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "B-cell Chronic Lymphocytic Leukemia", "Nodal Marginal Zone B-cell Lymphoma", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Small Lymphocytic Lymphoma", "Splenic Marginal Zone Lymphoma", "Waldenström Macroglobulinemia" ], "interventions": [ { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "yttrium Y 90 ibritumomab tiuxetan", "type": "RADIATION" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "total-body irradiation", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2004-06", "completion_date": "2016-04-23", "has_results": true, "last_update_posted_date": "2018-06-29", "last_synced_at": "2026-09-16T20:34:55.421Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00119392" }, { "nct_id": "NCT03610711", "title": "REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Gastroesophageal Cancer", "Immune Checkpoint Inhibition" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Relatlimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 21, "start_date": "2019-03-06", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-09-16T20:34:55.421Z", "location_count": 3, "location_summary": "Baltimore, Maryland • Pittsburgh, Pennsylvania • Dallas, Texas", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03610711" }, { "nct_id": "NCT07194044", "title": "Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Ewing Sarcoma" ], "interventions": [ { "name": "Vincristine", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Actinomycin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Liposomal doxorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": null, "sex": "ALL", "summary": "1 Year and older" }, "enrollment_count": 15, "start_date": "2026-02-05", "completion_date": "2030-10", "has_results": false, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-09-16T20:34:55.421Z", "location_count": 20, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Hartford, Connecticut + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07194044" }, { "nct_id": "NCT02137252", "title": "Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Invasive Breast Cancer (Stage I-III)", "Ductal Carcinoma in Situ", "Lobular Carcinoma in Situ", "Lobular Carcinoma", "Fatigue Related to Cancer Treatment" ], "interventions": [ { "name": "Naltrexone", "type": "DRUG" }, { "name": "Sugar Pill", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2014-05", "completion_date": "2015-08-01", "has_results": true, "last_update_posted_date": "2021-11-16", "last_synced_at": "2026-09-16T20:34:55.421Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02137252" }, { "nct_id": "NCT01058850", "title": "Phase I Rindopepimut After Conventional Radiation in Children w/ Diffuse Intrinsic Pontine Gliomas", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain Cancer", "Brain Stem Tumors", "Pontine Tumors" ], "interventions": [ { "name": "Rindopepimut", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Paul Graham Fisher", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "3 Years to 18 Years" }, "enrollment_count": 3, "start_date": "2011-06", "completion_date": "2013-09", "has_results": false, "last_update_posted_date": "2021-09-27", "last_synced_at": "2026-09-16T20:34:55.421Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01058850" }, { "nct_id": "NCT05800574", "title": "Lymphoscintigraphy Directed Elective Neck Radiation for p16+ Favorable Risk Oropharynx Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Oropharynx Cancer" ], "interventions": [ { "name": "Radiation therapy (5 days for 7 weeks)", "type": "RADIATION" }, { "name": "Radiation therapy (5 days for 6 weeks)", "type": "RADIATION" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "Fox Chase Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2023-03-14", "completion_date": "2027-09-23", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-09-16T20:34:55.421Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05800574" }, { "nct_id": "NCT01554397", "title": "Study With Intensity Modulated Radiation Therapy With Cisplatin to Treat Stage I-IVA Cervical Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Cervical Cancer" ], "interventions": [ { "name": "PET-guided Bone Marrow-Sparing Intensity Modulated Radiation Therapy (IMRT)", "type": "RADIATION" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "IMRT", "type": "RADIATION" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 101, "start_date": "2011-10-13", "completion_date": "2022-01-01", "has_results": true, "last_update_posted_date": "2024-11-29", "last_synced_at": "2026-09-16T20:34:55.421Z", "location_count": 2, "location_summary": "La Jolla, California • Miami, Florida", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01554397" }, { "nct_id": "NCT00251355", "title": "Gemcitabine, 5-Fluorouracil, and Radiation Therapy in the Treatment of Non-Metastatic Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "72 Years", "sex": "ALL", "summary": "18 Years to 72 Years" }, "enrollment_count": 40, "start_date": "1998-01", "completion_date": "2008-08", "has_results": false, "last_update_posted_date": "2016-12-20", "last_synced_at": "2026-09-16T20:34:55.421Z", "location_count": 3, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00251355" }, { "nct_id": "NCT00707343", "title": "[F-18] Fluorothymidine (FLT) Imaging on Patients With Primary Brain Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer", "Brain Tumors" ], "interventions": [ { "name": "FLT-PET Imaging", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2007-10-31", "completion_date": "2010-11-30", "has_results": true, "last_update_posted_date": "2021-10-15", "last_synced_at": "2026-09-16T20:34:55.421Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT00707343" } ] }